Introduction
Fusion of therapeutic proteins such as antibodies, cytokines and growth factors to homodimerization modules generates bivalent molecules generally displaying improved efficacy due to increased valency but also improved pharmacokinetic properties (Deyev and Lebedenko, 2008; Cuesta et al., 2010; Kontermann, 2010) . Furthermore, combining two different effector molecules allows for the generation of molecules with dual specificity. Such multivalent molecules can be applied for dual targeting approaches using bispecific antibodies or using bifunctional molecules composed of an effector molecule and an antibody moiety (Schrama et al., 2006; Deckert, 2009; Müller and Kontermann, 2010; Kontermann, 2012a,b) . Various homodimerization and multimerization modules have been described including the Fc region as well as C H 3, C H 4 and Ck domains of immunoglobulins (Hu et al., 1996; Jazayeri and Carroll, 2008; Giersberg et al., 2011) but also other protein domains and peptides, for example derived from streptavidin, p53, uteroglobin, tenascin and collagen (Pack and Plückthun, 1992; Dübel et al., 1995; Rheinnecker et al., 1996; Wüest et al., 2002; Fan et al., 2008; Ventura et al., 2009) . However, many of these modules are either non-human and/or are not covalently connected by disulfide bonds.
The heavy chains of IgM and IgE molecules contain an additional domain (C H 2, Cm2 and C12) in place of the hinge region connecting two heavy chains (Perkins et al., 1991; Beavil et al., 1995; Wan et al., 2002) . The IgM C H 2 domain (MHD2) consists of 111 amino acid residues (12.2 kDa) forming a homodimer covalently held together by a disulfide bond formed between cysteine residue 337 (EU index) of two domains . Each domain is further stabilized by an internal disulfide bond between cysteine residues 261 and 321 (see also Fig. 1 ) (Putnam et al., 1973) . Because of the central location of the MHD2 within the heavy chain, containing further heavy chain sequences at both ends, as well as its contribution to segmental flexibility (Roux et al., 1998; Løset et al., 2004) , the MHD2 should be ideally suited for the generation of dimeric fusion proteins composed of proteins fused to the Nand/or C-terminus. This should allow for the generation of multivalent and bifunctional molecules held together by the covalently linked dimerization domains.
Here, we analyzed the applicability of the MHD2 as homodimerization module to generate tetravalent, bispecific antibody-MHD2 as well as bifunctional antibody-MHD2-cytokine fusion proteins. These proteins were generated by fusing either single-chain fragment variable (scFv) molecules, a bispecific single-chain diabody (scDb) or an scFv and a single-chain derivative of TNF (scTNF) to the Nand C-terminus of the MHD2. We show that these fusion proteins can be produced in a dimeric form in mammalian cells retaining the bioactivity of the respective fusion partners.
Materials and methods

Materials
A humanized anti-epidermal growth factor receptor (EGFR) scFv (hu225) was generated from the antibody C225 (Goldstein et al., 1995) by complementarity-determining region grafting. The anti-human epidermal growth factor receptor 2 (HER2) scFv 4D5 was reproduced from published sequences (Carter et al., 1992) . Both scFvs as well as the sequence of the human MHD2 were codon-optimized for expression in human cells and synthesized by Geneart, now a Life Technologies subsidiary (Darmstadt, Germany), adding appropriate cloning sites. DNA encoding scDb EpCAMxEGFR was generated by combining the anti-EGFR hu225 V H and V L with the humanized anti-epithelial cell adhesion molecule (EpCAM) MOC-B V H and V L (Willuda et al., 1999) and cloning into pSecTagA as SfiI/NotI fragment. DNA encoding human scTNF was kindly provided by Peter Scheurich (University of Stuttgart, Germany). Plasmids containing the full-length open reading frame of human EGFR, HER2, HER3 and EpCAM were purchased from GeneCopoeia (EX-A275-M02, EX-Z2866-M02, EX-M0854-M02) or OriGene (RG201989). Cell lines were cultured in Roswell Park Memorial Institute 1640 medium (Invitrogen) supplemented with 5% fetal calf serum (FCS, HyClone) (HEK 293, HT1080, Colo205, NCI-H460, MEF-TNFR1, MEF-TNFR2) or 10% FCS (A431, SKBR3), respectively. Fluorescein isothiocyanate (FITC)-labeled antiHis-tag antibody was purchased from Dianova (Hamburg, Germany) and PE-labeled anti-His-tag antibody from Miltenyi Biotec (Bergisch Gladbach, Germany). Horseradish peroxidase (HRP)-conjugated anti-His-tag antibody was purchased from Santa Cruz (Heidelberg, Germany).
Production of MHD2 fusion proteins
DNA encoding the MHD2 variants and the MHD2 fusion proteins was cloned into expression plasmid pSecTagA (Invitrogen). Fusion proteins were produced from stably transfected HEK293 cells and purified from the cell culture supernatant by immobilized metal-ion-affinity chromatography as described elsewhere (Müller et al., 2007) . For sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), proteins were denatured in sample buffer (62.6 mM Tris-HCL, 5% glycerol, 2% SDS, 0.01% bromphenol blue, pH 6.8) and incubation for 5 min at 958C in the presence (reducing conditions) or absence (non-reducing conditions) of 5% v/v b-mercaptoethanol. The protein concentration was measured with a spectrophotometer (NanoDrop) using the calculated molar extinction coefficient. Aliquots were stored at -208C.
Production of soluble receptor and receptor-Fc fusion proteins
The extracellular domain of each receptor (amino acids 25-645 for EGFR, amino acids 23-652 for HER2, amino acids 20 -643 for HER3) was amplified from the plasmids by polymerase chain reaction with the following primers SfiI-EGFR-back (5 0 -CTC GCG GCC CAG CCG GCC CTG GAG GAA AAG AAA GTT TGC CAA-3 0 ), EGFR-NotI-for (5 0 -ATA GTT TAG CGG CCG CGG ACG GGA TCT TAG GCC CAT TCG T-3 0 ), SfiI-HER2-back 5 0 -CTC GCG GCC CAG CCG GCC ACC CAA GTG TGC ACC GGC ACA GAC-3 0 ), HER2-NotI-for (5 0 -ATA GTT TAG CGG CCG CCG TCA GAG GGC TGG CTC TCT GCT C-3 0 ), SfiI-HER3-back 5 0 -CTC GCG GCC CAG CCG GCC TCC GAG GTG GGC AAC TCT CAG GCA-3 0 ) and HER3-NotI-for (5 0 -ATA GTT TAG CGG CCG CTG TCA GAT GGG TTT TGC CGA TCA G-3 0 ) introducing SfiI and NotI restriction sites flanking the extracellular domains. Using these restriction sites, the receptor domains were cloned N-terminally to the human Fcg1 chain present in the eukaryotic expression vector pSecTagA-Fc (Müller et al., 2008) . Soluble EpCAM (sEpCAM) was produced by amplifying the extracellular domain (amino acids 24-265) using the primers AgeI-EpCAMec-back (5 0 -TAT ACC GGT CAG GAA GAA TGT GTC TGT GAA AAC-3 0 ) and EpCAMec-NotI-FLAG-Stop-XbaI-for (5 0 -C TAG TCT AGA TTA TTT ATC GTC ATC GTC TTT GTA GTC TGC GGC CGC TTT TAG ACC CTG CAT-3 0 ) followed by cloning into vector pSecTagA. Receptor-Fc fusion proteins were produced in HEK293 cells and purified using protein A affinity chromatography (TOYOPEARL w AF rProtein A-650F from Tosoh Bioscience) with yields of 2 -10 mg/l production medium. sEpCAM was produced in HEK293 cells and purified using FLAG affinity chromatography (Anti-FLAG M2 Affinity Gel, Sigma) with a yield of 0.16 mg/ml.
Enzyme-linked immunosorbent assay
Receptor-Fc fusion proteins and sEpCAM (100 ng/well) were coated overnight at 48C and remaining binding sites were blocked with 2% (w/v) dry milk/phosphate-buffered saline (PBS). Purified MHD2 fusion proteins were titrated in duplicates and incubated for 1 h at room temperature. Bound proteins were detected with mouse HRP-conjugated anti-His-tag antibody using 3,3 0 -5,5 0 tetramethylbenzidine (TMB) substrate (0.1 mg/ml TMB, 100 mM sodium acetate buffer pH 6.0, 0.006% H 2 O 2 ). The reaction was stopped with 50 ml of 1 M H 2 SO 4 . Absorbance was measured at 450 nm in an enzyme-linked immunosorbent assay (ELISA)-reader.
Flow cytometry
Binding of the fusion proteins to cells was determined by flow cytometry. Cells were incubated with antibodies and fusion proteins for 1 -2 h at 48C in PBS, 2% FBS, 0.02% NaN 3 (PBA). Cells were then washed with PBA and bound antibodies were detected with FITC-conjugated or PE-conjugated anti-His-tag antibody.
Size exclusion chromatography
High-performance liquid chromatography size exclusion chromatography (SEC) of fusion proteins was performed with a BioSuite 250 column (Waters Corporation, Milford, USA) and a flow rate of 0.5 ml/min. The following standard proteins were used: thyroglobulin, b-amylase, bovine serum albumin and carbonic anhydrase.
Melting point
Melting points of the MHD2 fusion proteins were determined by measuring thermal denaturation with the ZetaSizer Nano ZS (Malvern, Herrenberg, Germany). Approximately 200 mg of the MHD2 variants or 100 mg of purified MHD2 fusion proteins were diluted in PBS to a total volume of 1 ml and sterile filtered into a quartz cuvette. Dynamic laser lightscattering intensity was measured while the temperature was increased in 18C interval from 35 to 928C with 2 min equilibration for each temperature step. The melting point was defined as the temperature at which the light-scattering intensity increased.
Cytotoxicity assay
Mouse embryonic fibroblasts (MEF) stably transfected with either TNFR1-Fas (MEF-TNFR1-Fas) or TNFR2-Fas (MEF-TNFR2-Fas) (Krippner-Heidenreich et al., 2002) were seeded into 96-well cell culture plates and incubated for 16 h with increasing concentrations of scTNF or the MHD2 fusion proteins. Remaining cells were quantified by crystal violet staining.
Interleukin-8 secretion assay
HT1080 cells (2.0 Â 10 5 cells/100 ml) were grown in 96-well plates overnight. The next day, the medium was exchanged to remove constitutively produced interleukin (IL)-8, and the cells were incubated in duplicates together with serial dilutions of soluble scTNF, scFv-MHD2 or MHD2-scTNF fusion proteins for additional 18 h. Induction of IL-8 production and secretion into the culture supernatant was determined by an IL-8-Sandwich ELISA (ImmunoTools, Friesoythe, Germany) according to the manufacturer's protocol. In addition, cells were incubated with fusion proteins (20 pM) in the absence and presence of monoclonal antibodies trastuzumab or cetuximab (100 mg/ml) and analyzed for IL-8 secretion after 18 h of incubation.
Results
The MHD2 as dimerization module MHD2 (Fig. 1) was produced as C-terminally hexahistidyltagged protein in stable transfected HEK293 cells. SDS-PAGE revealed two bands under reducing conditions, the minor faster migrating band corresponding to the nonglycosylated form of the MHD2 (Fig. 1d) . Under nonreducing conditions, bands corresponding to disulfide-linked dimers were observed. Here, two major bands, corresponding most likely to dimers with one or two N-glycans, as well as a very faint band below the two bands, corresponding to the non-glycosylated dimer, were seen. Only a small fraction ( 5% as determined by densitometry) was not linked by disulfide bonds, indicating that the MHD2 alone is capable of forming covalently linked dimers. A melting point of 558C was determined by dynamic light scattering (Fig. 1e ). Furthermore, we tested three derivatives of the MHD2, one lacking the interdomain disulfide bond (MHD2-C337S), one lacking the N-glycosylation site (MHD2-N332Q) and a further variant lacking both (MHD2-C337S-N332Q) (Fig. 1c) . All MHD2 mutants were produced with similar yields as the wild-type MHD2 (0.8 -2.7 mg/l supernatant). The absence of the connecting disulfide bond in MHD2-C337S and MHD2-C337S-N332Q was confirmed by SDS-PAGE (Fig. 1d) . In SDS-PAGE, the MHD2-N332Q showed only a single band with a size identical with the faster migrating band observed for MHD2, thus confirming that the lower band corresponds to non-glycosylated protein.
MHD2-C337S-N332Q combined the features of both mutations. Dimeric assembly of all constructs was confirmed by SEC (not shown). All three MHD2 variants exhibited a reduced thermal stability compared with the wild-type MHD2 (Fig. 1e) . MHD2-C337S and MHD2-N332Q showed a reduction by 6 and 38C, respectively, while the melting point of the double mutant was reduced by 108C, indicating that the interdomain disulfide bond and the N-glycans contribute to stability of the MHD2.
Antibody-MHD2 fusion proteins
Two bivalent antibody-MHD2 fusion proteins were generated fusing either a humanized anti-EGFR scFv to the N-terminus of the wild-type MHD2 (scFv EGFR -MHD2; scFv A -MHD2) or an anti-HER2 scFv to the C-terminus of the MHD2 (MHD2-scFv HER2 ; MHD2-scFv B ), respectively. In addition, a tetravalent, bispecific fusion protein was produced fusing scFv A to the N-terminus and scFv B to the C-terminus of the MHD2 (scFv EGFR -MHD2-scFv HER2 ; scFv A -MHD2-scFv B ) (Figs. 2 and 3a) . All constructs were produced in stably transfected HEK293 cells with yields in the range of 1.5-2.5 mg/l supernatant, which is similar to yields obtained for various other recombinant proteins, e.g. scFv-IL-15 fusion proteins, scDb and scFv-Fc fusion proteins (Müller et al., 2008; Hopp et al., 2010; Hutt et al., 2012; Kermer et al., 2012) . SDS-PAGE analysis revealed under reducing conditions the expected molecular masses of the monomeric polypeptide chains ( 50 kDa for monospecific MHD2 fusion proteins and 75 kDa for bispecific MHD2 fusion protein) (see Fig. 3b ). Under non-reducing conditions all constructs showed a band corresponding to dimeric molecules, although a second band with the size of monomers was observed (Fig. 3b) . For the monospecific MHD2 fusion proteins, 80-90% of the molecules were present as disulfide-linked dimers, while for the bispecific MHD2 fusion protein 50% were disulfide linked.
Selectivity of the antibody-MHD2 fusion proteins was analyzed by ELISA using Fc fusion proteins of the extracellular region of EGFR, HER2 and HER3, respectively (Fig. 3c) . scFv EGFR -MHD2 showed a specific binding to EGFR and MHD2-scFv HER2 to HER2, while the scFv EGFR -MHD2-scFv HER2 fusion protein showed binding to both receptors. No binding was observed for the HER3-Fc fusion protein, included as negative control. Furthermore, we compared receptor binding in ELISA of scFv EGFR -MHD2 and MHD2-scFv HER2 with that of their monovalent scFvs (scFv EGFR , scFv HER2 ) (Fig. 3d) . ScFv EGFR -MHD2 bound with an EC 50 of 0.5 nM to immobilized EGFR-Fc, while scFv EGFR exhibited an 3-fold reduced EC 50 of 1.5 nM. Similar results were observed for MHD2-scFv HER2 , which bound with an EC 50 of 1.7 nM to HER2-Fc compared with 4.7 nM for scFv HER2 .
The antibody-MHD2 fusion proteins were further analyzed by flow cytometry for binding to different tumor cell lines expressing various amounts of EGFR and HER2 (Fig. 4) . The EGFR-expressing human epidermoid carcinoma cell line A431 showed strong binding of scFv EGFR -MHD2 and scFv EGFR -MHD2-scFv HER2 , while no or only marginal binding was detected for MHD2-scFv HER2 (Fig. 4a) . In contrast, the HER2-positive human breast adenocarinoma cell line SKBR3 showed strong binding of MHD2-scFv HER2 and scFv EGFR -MHD2-scFv HER2 and only weak binding of scFv EGFR -MHD2 (Fig. 4b) . The lung carcinoma cell line NCI-H460, expressing low amounts of EGFR and HER2, showed weak binding of scFv EGFR -MHD2 and MHD2-scFv HER2 but an increased binding of scFv EGFR -MHD2-scFv HER2 (Fig. 4c) . Similar results were observed for the human colon carcinoma cell line Colo205 (Fig. 4d) . Except for SKBR3, an increased binding was observed for the bispecific MHD2 fusion protein compared with the two monospecific MHD2 fusion proteins. 
analyzed by flow cytometry.
MHD2 as versatile module for the generation of fusion proteins
In a further approach, we fused a bispecific scDb molecule directed against EpCAM and EGFR to the N-terminus of MHD2 (Figs 2 and 5a) . The scDb-MHD2 fusion protein was produced in HEK293 cells with yields of 2 mg/l supernatant. Purified scDb-MHD2 migrated under reducing conditions with a molecular mass of 80 kDa and under non-reducing conditions with a major band corresponding to 125 kDa (Fig. 5b) . Specific binding of the purified scDb-MHD2 to EGFR-Fc and sEpCAM was demonstrated by ELISA (Fig. 5c) . Here, anti-EGFR scFv-MHD2 showed only binding to EGFR-Fc with a similar intensity as scDb-MHD2. Binding was also seen with EGFR and EpCAM-expressing cell lines including A431 that strongly express both antigens and Colo205 that show a weaker expression of EGFR and very strong expression of EpCAM (Fig. 5d) . Binding pattern of the bispecific scDb-MHD2 and the anti-EGFR scFv-MHD2 fusion protein were similar to that observed for the anti-EGFR and anti-EpCAM monoclonal antibodies ( Fig. 5d and e) .
Antibody-cytokine MHD2 fusion proteins
An antibody-cytokine MHD2 fusion protein was generated fusing the anti-EGFR scFv to the N-terminus of the MHD2 and a scTNF (Krippner-Heidenreich et al., 2008) to the C-terminus of the MHD2 (scFv-MHD2-scTNF). Furthermore, a bivalent cytokine-MHD2 molecule was generated lacking the scFv (MHD2-scTNF) (Figs 2 and 6a) . The two constructs were produced in HEK293 cells with yields of 5 -17 mg/l supernatant. SDS-PAGE showed under reducing conditions single bands corresponding to the molecular mass of the monomeric polypeptides (70 kDa for MHD2-scTNF and 100 kDa for scFv-MHD2-scTNF). Dimeric assembly was seen under non-reducing conditions with 40% of the MHD2-scTNF and 95% of the scFv-MHD2-scTNF present as dimers (Fig. 6b) . Dimeric assembly was confirmed by SEC ( Fig. 6c and e) . ScTNF, included for comparison, eluted at a major peak with an apparent molecular mass of 38 kDa. The MHD2-scTNF molecule revealed a major peak of 180 kDa and the scFv-MHD2-scTNF showed a major peak corresponding to 230 kDa. Melting points were also determined for the two fusion proteins. ScTNF and MHD2-scTNF had a melting point at 778C (not shown), while the data obtained for scFv-MHD2-scTNF indicated two melting points, one at around 608C as observed for scFv EGFR -MHD2 (not shown), and one at 778C (Fig. 6f) .
In ELISA, the scFv-MHD2-scTNF fusion protein showed specific binding to an EGFR-Fc fusion protein, while no binding was observed for MHD2-scTNF (Fig. 7a) . Binding to EGFR was further confirmed by flow cytometry with EGFR-expressing cells lines A431 and HT1080 (human fibrosarcoma cell line) (Fig. 7b) . Binding of scFv-MHD2-scTNF to both cell lines could be blocked by preincubation with cetuximab. No or only marginal effects were observed with trastuzumab (anti-HER2). Furthermore, binding of scTNF, MHD2-scTNF and scFv-MHD2-scTNF to TNFR1-Fc and TNFR2-Fc fusion proteins was shown in ELISA (Fig. 7c) .
Next, the fusion proteins were tested for triggering cell death on MEF stably transfected to express either the extracellular region of human TNFR1 (MEF-TNFR1) or TNFR2 (MEF-TNFR2) fused to the transmembrane and cytoplasmic region of Fas (Krippner-Heidenreich et al., 2002) . These cell lines allow to discriminate between the action of soluble TNF and membrane-bound TNF (mTNF), with mTNF or multimeric TNF required to active MEF-TNFR2. A titration of scTNF, MHD2-scTNF and scFv-MHD2 showed a strong cytotoxic activity of scTNF and MHD2-scTNF on MEF-TNFR1, while on MEF-TNFR2 cell killing was only induced by the dimeric MHD2-scTNF construct (Fig. 8a and  b) . ScFv-MHD2 was inactive on both cell lines.
Bioactivity of the MHD2-scTNF fusion proteins was further analyzed by measuring the TNF-mediated secretion of IL-8 from HT1080 cells. ScTNF as well as the MHD2-scTNF fusion protein induced secretion of IL-8 in a concentration-dependent manner with EC 50 values of around 200 pM (Fig. 8c) . A strongly increased stimulatory activity was observed with scFv-MHD2-scTNF, with an optimum at around 20 pM. At higher concentrations, the IL-8 release declined to 25% of the highest values. The scFv-MHD2 fusion protein lacking the scTNF moiety, included as negative control, showed no stimulatory activity. IL-8 secretion induced by scFv-MHD2-scTNF was almost completely blocked to the level induced by the untargeted MHD2-scTNF fusion protein and scTNF with excess amounts of cetuximab directed against the same epitope, while trastuzumab had no effect. Both antibodies did not affect IL-8 secretion induced by MHD2-scTNF and scTNF, respectively (Fig. 8d) .
Discussion
The MHD2 is a small N-glycosylated domain mediating and stabilizing dimerization of two IgM heavy chains . As revealed by data obtained for the various mutants, the MHD2 homodimers are stabilized by a natural existing intermolecular disulfide bond formed between cysteine residue 337 of each domain. Furthermore, we could show that the N-glycans attached to residue 332 contribute to the stability of the MHD2. Because of the presence of naturally occurring interdomain disulfide bond there is no need of an additional insertion of a cysteine residue, for example, utilized in small immunoprotein molecules, which are based on the C H 4 domain of IgE (Borsi et al., 2002) . The MHD2 is located in the center of the IgM heavy chain flanked at both sides by further heavy chain domains, thus N-and C-termini are located at opposite ends of the domain. Therefore, fusing proteins either to the N-terminus or the C-terminus or to both sides should not interfere with the ability of MHD2 to form dimers and to display the fusion partners in active form. Here, we used scFv fragments, a bispecific scDb and a scTNF to demonstrate feasibility to generate bivalent and tetravalent molecules. In other modules, for example uteroglobin, both termini are present on the same side of the molecule resulting in a rather crowded display of the fused moieties (Ventura et al., 2009) . Furthermore, uteroglobin dimers are capable of binding progesterone (Peter et al., 1989) , which might be, based on its anti-inflammatory activity, useful as add-on for the therapy on inflammatory diseases (Mukherjee et al., 2007) . However, this might also limit its use for other indications. In contrast, the MHD2 itself has no effector functions, thus is biologically inert and because of the abundant presence of IgM in serum, nonimmunogenic. The MHD2 domain also allows to simultaneously fuse proteins to the N-and C-terminus. In contrast, for other domains, for example, triplex-forming collagen-like peptides (collabodies), it was shown that they are only able to trimerize when proteins were fused either to the N-or the C-terminus (Fan et al., 2008) . SDS-PAGE analysis under non-reducing conditions confirmed covalent linkage of the two MHD2 polypeptides, although to varying extent. In SEC major peaks were observed corresponding to dimeric molecules, indicating that the MHD2 domains are held together even in the absence of disulfide bonds, which was confirmed by studies with the MHD2 C337S mutants. This is in accordance with results described for a mutated IgM-molecule, in which the cysteine residue at the position 337 was substituted to a serine (IgM-Ser337), and thus the intermolecular disulfide bond was not formed . Analysis of the sedimentation rates of IgM-Ser337 showed that 65% of the molecules were in a pentameric or hexameric form. It was concluded that these polymers must be held together at least partly non-covalently because besides dimers and some larger forms, they could detect monomers in SDS-PAGE analysis .
Homodimerization through the MHD2 domain offers the possibility to produce multivalent and multifunctional molecules. By fusing targeting moieties with different specificity to MHD2, the binding of the dimeric protein is increased by avidity effects and the possibility to recognize two different antigens on the target cells. In our study, we could show that a bispecific scFv-MHD2-scFv fusion protein directed against EGFR and HER2 bound specifically to their respective receptors in ELISA and to the respective receptor-expressing cell lines in flow cytometry analysis, which revealed an increased binding compared with the monospecific fusion proteins, thus indicating cooperative binding of the different binding sites of the bispecific fusion protein.
The bifunctional antibody-cytokine MHD2 fusion protein exhibited binding to antigen-positive tumor cells and an improved bioactivity compared with monovalent scTNF. The binding specificity was confirmed by incubation with cetuximab, which prevented binding of scFv EGFR -MHD2-scTNF. TNFR1 is activated by both mTNF and soluble TNF, whereas TNFR2 can only be activated by membrane-bound MHD2 as versatile module for the generation of fusion proteins TNF (mTNF), i.e. by multiple cross-linking (Grell et al., 1995 (Grell et al., , 1998 . ScTNF and the MHD2-scTNF fusion proteins were able to induce apoptosis in MEF-TNFR1 cells. Here, the dimeric MHD2-scTNF fusion protein was slightly more potent than scTNF. Importantly, the MHD2-scTNF fusion proteins, displaying two functional scTNF molecules, were capable of inducing apoptosis in TNFR1-Fas and TNFR2-Fas transfected MEF cells, thus mimicking the activity of mTNF.
Furthermore, on HT1080 the targeted dimeric scFv EGFR -MHD2-scTNF fusion protein exhibited a strongly increased stimulatory activity compared with MHD2-scTNF and scTNF. HT1080 cells express TNFR1 but not TNFR2 and can, therefore, be activated by soluble and membrane-TNF (Gerspach et al., 2006) . Accordingly, scTNF and the dimeric MHD2-scTNF showed a similar activity on these cells. Our findings indicate that delivery of scTNF to EGFR-expressing cells through the scFv moiety results in an accumulation of the molecules on target cells, thus further improving bioactivity. The targeting effect was confirmed by blocking experiments with cetuximab, which reduced the cytotoxic activity of the scFv EGFR -MHD2-scTNF fusion protein to that of the non-targeted MHD2-scTNF fusion protein and scTNF.
In summary, we show that MHD2 is a versatile tool to build homodimeric fusion proteins allowing fusion of proteins to the N-terminus and/or the C-terminus without interfering with their bioactivity. Various formats of MHD2 fusion proteins were developed using scFv and bispecific scDb as binding moieties, yielding monospecific, bivalent and bispecific, tetravalent molecules. Furthermore, tetravalent antibody-cytokine fusion proteins were generated combining targeting with cytotoxic activities. Obviously, future work has to address also further optimization, e.g. modifying the linker length and composition to improve stability and covalent linkage of the domains. Nevertheless, the modular composition of the MHD2 fusion proteins allows to combine a variety of molecules, including other targeting moieties (e.g. peptides, antibody-mimicking protein scaffolds and bispecific molecules) (Nuttall and Welsh, 2008; Chan and Charter, 2010; Carter, 2011; Löffblom et al., 2011; Kontermann, 2012a) and other effector molecules (e.g. toxins, cytokines, growth factors, hormones and enzymes), thus opening additional applications for therapy and diagnosis (Andrady et al., 2007; Pastan et al., 2007; Lin et al., 2011; Kontermann, 2012b; Scott et al., 2012) .
